Roche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or ...

Against all the odds, Roche's Genentech unit has won FDA approval for its clot-busting drug TNKase as a treatment for acute ischaemic stroke, after all but abandoning the project a couple of years ...

Monday, the Roche subsidiary added a second stroke treatment to its repertoire, gaining an FDA endorsement for TNKase (tenecteplase). The tissue plasminogen activator, clot-dissolving ...

TNKase is designed to target clots better and last longer than natural tPA. Genentech, part of the Roche group, said in a press release that TNKase can be given quickly, unlike Activase ...

Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in acute ischaemic stroke (AIS). The drug, which has been authorised for use in ...

TNKase will be available for the treatment of acute ischemic stroke in adults, joining the Roche subsidiary’s Activase (alteplase) on the market – also approved for the same indication.

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...

The group was founded in 1896 by Fritz Hoffman-La Roche, whose descendants still have a controlling stake. Roche originally sold consumer-focused medicines like cough syrup, vitamins and Valium ...